Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
-
Published:2024-09
Issue:9
Volume:9
Page:103696
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Gallois C., Bergen E.S., Auclin É., Pernot S., Higué J., Trouilloud I., Touchefeu Y., Turpin A., Mazard T., Sartore-Bianchi A.ORCID, Prenen H.ORCID, Alberti A.ORCID, Pilla L.ORCID, Cuissy S., Wookey V., Perret A., Melchior C., Artru P.ORCID, Dubreuil O.ORCID, Drouillard A.ORCID, Doat S.ORCID, Lavolé J.ORCID, Basile D.ORCID, Perkins G., Jary M., Stintzing S.ORCID, Jos J.ORCID, Tougeron D.ORCID, Taieb J.ORCID
Reference36 articles.
1. Exploring the best treatment options for BRAF-mutant metastatic colon cancer;Taieb;Br J Cancer,2019 2. Characteristics of BRAFV600E mutant, deficient mismatch repair/proficient mismatch repair, metastatic colorectal cancer: a multicenter series of 287 patients;de la Fouchardière;Oncologist,2019 3. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma;Delord;Clin Cancer Res,2017 4. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial;Dummer;Lancet Oncol,2018 5. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial;Planchard;Lancet Oncol,2016
|
|